$HRTX

Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -150.00% and -0.91%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Original reporting
Zacks Commentary · Zacks Equity Research
Published Nov 4, 2025, 2:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 5, 2025, 12:02 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates — source image
Decision brief

The 30-second read

$HRTXBearishMed
01

Why it matters

The earnings miss could lead to short-term selling pressure, but long-term prospects depend on upcoming product approvals and pipeline success.

02

Market read

The news is highly relevant for traders holding or considering trading HRTX, especially in the short term.

03

What to watch

Potential upcoming catalysts such as pipeline developments or strategic partnerships that might offset recent losses.

Timing: Immediate, as the earnings report was published on 2025-11-04.

Background

Heron Therapeutics reported a significant Q3 loss, missing revenue estimates, which has raised concerns among investors about its growth trajectory.

Company-level read

Ticker impact

$HRTXBearishMedium confidence
Context

Heron Therapeutics' recent quarterly earnings report indicates significant losses and revenue misses, which could influence investor sentiment and stock performance.

Expected impact

Likely short-term decline of 5-10%, with potential for further downside if negative sentiment persists.

Evidence & confidence

The substantial earnings miss and revenue shortfall are typical catalysts for downward price movement, but market reaction may be tempered by broader sector trends and company-specific factors.

Market effects

Potential negative impact on biotech and pharmaceutical sectors due to earnings disappointment.

Limited regional impact; primarily affecting US-based biotech stocks.

Minimal, as the news pertains to a US-focused biotech company.

Counterpoint

The stock may have already priced in the earnings disappointment, and positive news or sector recovery could lead to a rebound.

Key entities

  • Heron Therapeutics

    A biotechnology company focused on developing and commercializing therapies for cancer and other serious diseases.

Related articles

$HRTXMedAI 8/10

Heron Therapeutics Q2 Earnings Call Highlights

Heron Therapeutics (NASDAQ:HRTX) reported Q2 sales of about $4.2M for APONVIE, up 26% QoQ and 74% YoY, and $21.8M for CINVANTI, down about 10% YoY. SUSTOL contributed $0.5M as wind-down continued. Heron posted a Q2 net loss of $5.5M, gross margin 69.3%, and ended with $42.7M cash equivalents. It amended its Hercules credit facility with a $13.5M principal reduction and potential $4M more, and withdrew 2026 guidance.

$HRTXMed

HERON THERAPEUTICS, INC. /DE/ (HRTX): Results of Operations and Financial Condition

HERON THERAPEUTICS, INC. /DE/ (HRTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 hrtx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Heron Therapeutics Announces Second Quarter 2026 Financial Results - Q2 2026 net revenue of $37.7 million, up 9% from the first quarter of 2026; ZYNRELEF ® net revenue grew 35% and APONVIE ® net revenue grew 74% year-over-yea

$NVDAMed

Nvidia teams up with Wall Street asset managers on $500 billion AI infrastructure push

CNBC reports Nvidia is working with Apollo, Blackstone, BlackRock’s Global Infrastructure Partners, Brookfield, Goldman Sachs and KKR on a planned $500 billion financing push for AI infrastructure, citing an unnamed source. An announcement could come as soon as Monday, according to the report. The effort would help customers finance Nvidia GPUs and data centers, including power capacity needs.

$ARTWMed

Art's-Way Manufacturing Co.: Art's Way Announces Significant Increase in Backlog Following Award of Major Modular Building Projects

Art's-Way Manufacturing Co. (Nasdaq:ARTW) said its Modular Buildings segment backlog rose to over $19.0 million after winning major modular building projects. The company cited a prior $1.3 million backlog in its May 31, 2026 10-Q. It expects fulfillment by end of fiscal 2027, subject to schedules and milestones, with margins generally consistent with historical performance.